English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

and Objectives: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic inflammatory syndrome characterized by pain, pressure or discomfort in the bladder and accompanied by urinary symptoms of frequency and urgency. AQX-1125, a novel SH2containing inositol-5’-phosphatase 1 (SHIP1) activator with broad anti-inflammatory properties, represents a potential once-daily, oral therapy for IC/BPS. In rats, a single injection of cyclophosphamide (CYP) induces a chemical cystitis with similar features of IC/BPS, including inflammation of the bladder, visceral pain and an increase in urinary frequency. The aim of this study was to evaluate the effect of AQX-1125 (0.3, 3 and 30 mg/kg doses) on visceral pain, inflammation and cystometric parameters in acute CYP-induced cystitis in rats.

MP72-17 EFFECT OF AQX-1125 ON URINARY BLADDER INFLAMMATION AND PAIN INDUCED BY CYCLOPHOSPHAMIDE IN RATS, BY TARGETING THE SHIP1 PATHWAY